Company Overview
Snapshot
Founded in November 2005 by Professor Yechezkel Barenholz, LipoCure operates with 1-10 employees. The company has raised $8 million across one funding round from two investors, including Integra Holdings. In June 2018, Virpax Pharmaceuticals licensed LipoCure's liposome drug delivery technology.
Business overview
LipoCure develops therapeutics utilizing proprietary liposome-based nano drugs, featuring novel drug-loading capabilities and controlled drug-release mechanisms. Its platform enables remote drug loading into nano-liposomes for targeted delivery, aiming to enhance permeability and retention, improve therapeutic effects, and reduce side effects. The technology is applicable to established drugs for conditions such as rheumatoid arthritis, multiple sclerosis, and cancer, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery.
Strategic signal
In June 2018, Virpax Pharmaceuticals licensed LipoCure's liposome drug delivery technology. This strategic partnership validates LipoCure's proprietary platform and its potential for broader application in pharmaceutical development, signaling market interest in its advanced nano drug delivery solutions.
Log in to access full profile ›Company Intelligence Q&A
- When was LipoCure founded?
- LipoCure was founded in November 2005.
- Who is the founder of LipoCure?
- Professor Yechezkel Barenholz is the founder of LipoCure.
- What is LipoCure's primary focus?
- LipoCure focuses on developing therapeutics using proprietary liposome-based nano drugs with novel drug-loading and controlled drug-release mechanisms.
- Which company licensed LipoCure's technology?
- In June 2018, Virpax Pharmaceuticals licensed LipoCure's liposome drug delivery technology.
- What is the total capital raised by LipoCure?
- LipoCure has raised $8 million across one funding round.